Evidence for immunity to SARS-CoV-2 from epidemiological data series [version 2; peer review: 1 not approved]

Pablo Yubero, Alvar A. Lavin, Juan F. Poyatos

Logic of Genomic Systems Laboratory (CNB-CSIC), Madrid, 28049, Spain

First published: 27 Jan 2021, 10:50
https://doi.org/10.12688/f1000research.28482.1
Latest published: 14 May 2021, 10:50
https://doi.org/10.12688/f1000research.28482.2

Abstract
The duration of immunity to SARS-CoV-2 is uncertain. Delineating immune memory typically requires longitudinal serological studies that track antibody prevalence in the same cohort for an extended time. However, this information is needed in faster timescales. Notably, the dynamics of an epidemic where recovered patients become immune for any period should differ significantly from those of one where the recovered promptly become susceptible. Here, we exploit this difference to provide a reliable protocol that can estimate immunity early in an epidemic. We verify this protocol with synthetic data, discuss its limitations, and then apply it to evaluate human immunity to SARS-CoV-2 in mortality data series from New York City. Our results indicate that New York's mortality figures are incompatible with immunity lasting anything below 105 or above 211 days (90% CI.), and set an example on how to assess immune memory in emerging pandemics before serological studies can be deployed.

Keywords
COVID-19, immunological memory, compartmentalized epidemiological models, data assimilation

This article is included in the Emerging Diseases and Outbreaks gateway.

This article is included in the Coronavirus collection.
Introduction

The presence and duration of immunity to novel viruses is traditionally determined through longitudinal serological studies. By characterizing antibodies against a problem virus and tracking the serum levels of these antibodies in a population, for a long enough period, it can be determined with a solid standard of evidence whether the virus induces immunity and how long that immunity lasts.

This method for studying immunity is statistically reliable, but it can demand a very long time and requires ample human and technical resources. Such caveats do not usually pose a problem, but they have become relevant in the case of the recent 2019 coronavirus outbreak. COVID-19 presents the right combination of infectivity and mortality to cause a pandemic of unprecedented global proportions that become clinically and economically relevant in very short timescales, far exceeded by those required for longitudinal serological studies.

Common human coronaviruses causing cold and flu-like symptoms of mild degree typically leave an immune memory lasting from six to twenty-eight months. The determinants of coronavirus and rhinovirus immunity have been widely studied for decades and are moderately well understood, as are those of influenza. These diseases leave some immunity, but they can reinfect patients as soon as half a year after.

The mechanisms enabling reinfection strive from simple to elaborate. In the case of influenza and rhinoviruses, highly polymorphic proteins change yearly or faster and thus pathogens escape immune memory through mutation: they are virtually a new pathogen. There is also some evidence that homologous recombination may contribute to multi-wave influenza outbreaks. Due to previous infections generating an insufficient or non-lasting immune response, recovered patients can become infected again. Other human pathogens such as herpes virus, human cytomegalovirus (HCMV), and human immunodeficiency virus (HIV) elude immunity without fully leaving the human body. This persistence in the face of immune surveillance and medicine is not unique to viruses, as it is well documented in bacteria and tumor cells. The populations of these cellular pathogens achieve persistence through the complex interplay of different factors, including extrinsic and intrinsic noise in therapeutic targets, mutation, directly compromising immune function, subpopulations with distinct growth rates, and other phenomena. In viruses, lysogeny often plays a pivotal role, as it may do infection of immune cell types.

SARS-CoV-2 is phylogenetically a coronavirus, so the standard of evidence by default would indicate that it induces immunity lasting from one to two years. However, since early in the pandemic, recovered patients have tested positive after previously testing negative. For a while, this rose concerns that SARS-CoV-2 could be not inducing immunity, or persisting in the body after recovery. It is now becoming evident that these positives at least were induced by harmless remains of viral material that endure in the human bloodstream weeks after disease has subsided. But, could immunity after infection be virtually non-existing after all? The presence, extent, and particularities of human immunity to SARS-CoV-2 are still relevant for academics, health professionals and the broader public, and require further research.

Serological studies are the main tool to that aim and continue to unfold as we write this study, with preliminary results already being published. In the meantime, lack of further evidence on human immunity to SARS-CoV-2 delays our full understanding of COVID-19, leads to mismanagement of medical resources such as masks in conditions of scarcity (as the ones we have seen during this pandemic), and sets recovered patients as putative contagion sources, among other undesirable outcomes.

Theoretical alternative approaches to detecting immunity would be desirable in these circumstances; and in principle identifying immunity times should be as simple as inferring the value of a free parameter by fitting an epidemiological model to field data. However, nonlinear dynamical systems like those characteristic of epidemics have a high degree of inherent uncertainty, which makes prediction through conventional, deterministic means inefficient. System variables such as the population of infectious or recovered patients may follow any of a wide array of possible trajectories, and we cannot know which one they will take until they do so.

Despite these hurdles, data assimilation techniques are a set of mathematical tools that have provided success in forecasting epidemics. Within these methods, ensemble adjustment Kalman filters (EAKF) have shown capable of providing accurate predictions in a system with many variables.

By using Bayes’s theorem to update a model’s predictions with observations at a series of points, uncertainty in a further forecast is reduced, and the span of possible posterior trajectories is limited. The better the measurements (having less uncertainty themselves than the predictions) and the closer in time to the present, the better the updated forecast will be. These Bayesian approaches were originally developed in the context of large-scale geophysical problems and readily and most notably applied to weather predictions. More recently, they have been adapted to epidemiology too, where they became the state of the art in epidemiological forecasting, also in the COVID-19 pandemic, e.g., see also for a related method.

Here, we first examine the impact of immunity memory in the dynamics of a sound epidemiological model of COVID-19. We then estimate the capacity of EAKF techniques to infer the duration of this memory and then apply this approach to mortality time series from New York City (NYC), discerning
immunity times against SARS-CoV-2 with reasonable accuracy. Finally, we examine the implications of the presence of immunity in the post-pandemic dynamics. This work thus provides reliable information about human immunity to SARS-CoV-2 and also represents an alternative to longitudinal serological studies for use against future emergent pandemics.

Results
Impact of immunity memory on a COVID-19 epidemiological model
We used an epidemiological model in which the total population is divided into a number of classes\(^1\) (Figure 1). The specific compartments represent our current understanding of COVID-19 progression. Note that the infected population is divided into five (right column in Figure 1) and that we also included two different mortality rates for critical cases because mortality depends strongly on whether there are available beds in Intensive Care Units (ICUs; Methods and Extended data for the model details). All associated parameters in this model are available except for the infection rate \(\beta\) and the immunity memory \(\tau\) (Extended data). The fundamental categories resemble those of the well-known SEIRS model\(^7\) in that the recovered population becomes susceptible after some duration of immunity (\(\tau\)). However, the particularities of the COVID-19 progression are such that a minimal SEIRS cannot predict the mid- and long-term dynamics of the population well enough (Extended data and Figure S1).

In addition, we performed a variance-based global sensitivity analysis\(^11,22\) of the model (Extended data and Figure S2). In particular, it illustrates the importance of the parameters related to the mild cases in shaping the deceases time series, the peak height and the total number of deceases after a year of pandemic whereas the infection rate tunes mainly the timing of the pandemic peak.

First, we study how the loss of immunity after infection impacts daily deaths (dD/dt) in our COVID-19 epidemiological model. The initial condition is a single exposed case, with a constant and intermediate value of the infection rate (Figure 2A). We find analytically that in the short term, i.e., during the exponential growth of infected cases, the development of immunity has no effect on the initial number of secondary infections \(R_0\) (Extended data): there is not enough time for the re-circulation of the recovered back to the susceptible population.

However, in the mid-term of the epidemic starting at the departure from exponential growth and up to the first noticeable reduction in daily deceases, a shorter immunity memory time raises the overall number of daily deceases. It also promotes a more prolonged duration of the epidemic as estimated by the time daily deceases stay above 75% of the maximum. Finally, in the long term, beyond the first peak, a finite immunity memory promotes the appearance of new epidemic waves.

---

\(^1\)We refer to the basic reproductive number as the initial number of secondary infections, and to the effective reproduction number as the effective number of secondary infections.

---

**Figure 1.** COVID-19 epidemic model. We introduce a compartmentalized epidemiological model with five infected categories (gray shading). Note that the accessibility of ICUs determines the rate to deceased and that those individuals recovered after infection may lose their immunity and become again susceptible after a finite time \(\tau\) (red arrow). See Extended data for model details.

**Figure 2.** The immunity memory \(\tau\) impacts differently in the mid- and long-term dynamics. (A) Different time series of daily deceases depending on the value of the immunity memory \(\tau\) (\(\beta = 0.5\) days\(^{-1}\)). (B) The peak height, i.e. maximum number of deceased individuals in a single day, and the duration of the “first-wave” (inset) increase with shorter immunity times. However, the former increases with the infection rate, as opposed to the latter. (C) A finite value of immunity memory induces intrinsic seasonality on the model what produces subsequent epidemic peaks with time. This seasonality depends heavily on the interplay between the infection rate and the immune memory. Data shown for \(\tau = 3\) months.
The duration of the immunity time also shapes the dependence with $\beta$ of the peak number of daily cases $dD/dt_{\text{peak}}$ and the duration of the epidemic (Figure 2B). As expected, $dD/dt_{\text{peak}}$ increases with the infection rate $\beta$ but decreases for increasing $\tau$. In addition, we observe that $dD/dt_{\text{peak}}$ for $\tau$s beyond a threshold are hardly distinguishable, e.g., data for $\tau = 3$ months and $\tau = 1$ year. Moreover, the duration of the first peak decreases together with both increasing $\beta$ and $\tau$. Figure 2C displays the intrinsic seasonality derived from a finite immunity time. The height and timing of the secondary peaks are strongly dependent on both $\beta$ and $\tau$, data shown is for a fixed value of $\tau = 3$ months. This subscribes earlier projections obtained with a multi-strain model\textsuperscript{13}.

Predicting immunity memory of an ongoing epidemic

A finite value of the immunity time impacts the time series of daily deceases only after the exponential growth, and starting around the peak of the first wave. To notice these implications, we required a considerably advanced epidemic. What about an ongoing epidemic? This would need the real-time assessment of the epidemic parameters and the ability to forecast the short-term dynamics after the epidemic passes the peak.

While this kind of forecasting is intrinsically difficult\textsuperscript{11},\textsuperscript{13}, it is now possible to apply filtering techniques that recently demonstrated validity in this problem by integrating model predictions and data\textsuperscript{11,14,23,24}. We thus adopted a specific recursive filtering technique known as EAKF to infer the immunity memory duration in the course of an ongoing epidemic (see Extended data for a brief intro to EAKF\textsuperscript{11,14}.

To describe a typical scenario, we first simulated a synthetic time-series with the deterministic model that would represent real data (Figure 3A–C). We then ran 100 independent iterations of the EAKF protocol, with different initial conditions, to estimate $dD/dt$ (everyday deaths) and the “hidden” parameters ($\beta_{\text{synth}}$ and $\tau_{\text{synth}}$). To assess the performance of our protocol, we compute the relative errors between the target values and the median of predictions. The similarity between the predicted and real curve of $dD/dt$ is evident (Figure 3A). Note that the estimates of $\beta$ and $\tau$ improve mostly before and after the epidemic peak, respectively (Figure 3B–C). This trend is in agreement with our results from the previous section.

To further evaluate the limits of this approach, we generated a test bed of 100 synthetic data series for a range of parameters (note that for each series we ran again 100 iterations). Specifically, each series correspond to random values of $\beta_{\text{synth}} \in [0.2, 1.5]$ days\textsuperscript{-1} and $\tau_{\text{synth}} \in [0, 360]$ days to which we added relative random noise normally distributed with zero mean and standard deviation up to 10%. The initial exposed population is also selected randomly from a uniform distribution $E_{\text{synth}}(t = 0) \in [0, 10]$. The goal is to apply EAKF within this range to estimate once again the $dD/dt$ series and the “hidden” parameters. Figure 3D–E shows the performance of our protocol when applied to the entire test bed of synthetic data. On the one hand, we find that infection rates $\beta < 1$ are excellently captured whereas $\beta > 1$ are slightly overestimated (Figure 3E). On the other hand, $\tau$ is more difficult to estimate in its entire range (smaller correlation between model and synthetic values), but the estimates are not biased towards

![Figure 3. Our EAKF-based approach predicts well the parameters of an ongoing epidemic with synthetic data.](image) We tested the performance of the EAKF-based protocol over a test bed of synthetic data made of 100 time-series generated with the model and random values of $\beta$ and $\tau$. Panels A–C illustrate the analysis of a single example whereas panels D–F show the overall performance on the entire test bed. (A) Our protocol (blue) is able to accurately capture data of daily deceases (red), with a linear correlation between data and model $\rho > 0.99$. (B) The value of the synthetic infection rate $\beta_{\text{synth}}$ (dotted line) is captured by the protocol $\beta_{\text{model}}$ (blue) after some data assimilation steps, and prior to the pandemic peak. Accordingly, the relative error between $\beta_{\text{synth}}$ and $\beta_{\text{model}}$ decreases as more data is assimilated (purple solid, right y-axis). (C) The immune memory $\tau_{\text{model}}$ (blue) follows similar dynamics as $\beta_{\text{model}}$ and approaches the synthetic value $\tau_{\text{synth}}$ (dotted line). However, its relative error (purple solid, right y-axis) drops later than $\beta_{\text{model}}$ at about the epidemic’s peak, in agreement with the results of our previous section. In panels A–C, shadings represent 95\%CI, while vertical lines denote time of peak. (D) Histogram of linear correlations between model and data of daily deceases (as in panel A) for the entire test bed. (E–F) Synthetic values and EAKF estimates of the infection rate and immune memory largely correlate, $\rho = 0.99$ and $\rho = 0.98$, respectively. We find however that our protocol tends to overestimate larger infection rates when $\beta_{\text{synth}} > 1$. 

Page 5 of 16
upper/lower values (Figure 3F). Moreover we found that the errors between estimates of \( \tau \) and \( \beta \) barely correlate (\( \rho = -0.18 \), not shown), so a better estimation of \( \beta \) does not necessarily lead to a worse estimation of \( \tau \). Also, neither errors in the estimates of \( \tau \) nor \( \beta \) correlate with the magnitude of the noise added to \( \text{dD/dt} \) (\( \rho = 0.04 \) and \( \rho = -0.12 \), respectively; not shown).

In sum, filtering and data assimilation techniques successfully identify the values of the infection rate, \( \beta \), and immunity memory, \( \tau \), when enough data points are available. The value estimates are robustly captured for different initial conditions. Finally, we also found that our protocol can handle up to 10% relative errors with little to no impact on the estimation of \( \beta \) and \( \tau \).

Quick and strong social distancing measures conceal the mid-term effect of immunity

We now apply the protocol used in the previous section to real time series of new daily deceases reported for COVID-19 in different heavily-affected regions. We performed a preliminary test to rank these regions (world-wide countries and counties/cities within the US) to narrow down potential candidates for signal detection. From over 30 regions, we selected NYC because it had the largest number of deceases per \( 10^8 \) inhabitants and it did not exhibit volatile field data like other regions, e.g. Nassau (NY, USA) or Belgium, (Extended data: Figures S3 and S4).

To be certain that the signal in \( \tau \) is not an artifact, we added to the protocol a control variable \( \delta \) that has no effect on the model, it is initialized as a different sample of the same initial distribution as \( \tau \) and follows the same update rules as \( \tau \). Whether immunity should be considered in the model will depend on its behavior relative to the control variable. The influence of \( \tau \) becomes relevant in the model whenever its distribution deviates significantly from that of \( \delta \). On the contrary, if immunity mimics the behavior of the control variable it demonstrates that \( \tau \) has no role in shaping the epidemiological dynamics. Thus, statistically significant deviations between the distributions of \( \tau \) and \( \delta \) highlight the influence of \( \tau \) in the results.

In Figure 4A–C we show the results of NYC. The success of the EAKF protocol to capture the dynamics of \( \text{dD/dt} \) is apparent with a root mean squared error RMSE=18 deceases and a linear correlation between data and the model median \( \rho > 0.99 \) (Figure 4A). In particular, our protocol also captures the time-dynamics of the infection rate, which is well aligned with the days on which NYC promoted social distancing measures: schools and library closings on March 16th, and the pause order of March 22nd (Figure 4).

Most importantly, we found a final estimate of \( 105 < \tau < 211 \) days with 90% confidence (\( 80 < \tau < 288 \) days with 95% CI). We obtained this estimate from a statistically significant change in the distribution of \( \tau \) with respect to the control variable \( \delta \) (two-sample Kolmogorov Smirnov, \( p = 0.017 \)). The
upper bound should be considered with caution, given the limited availability of COVID-19 data due to its recent appearance, and future data assimilation steps could alter this bound.

We attribute the difficulty to capture the value of $\tau$ in real data as opposed to synthetic data to the ubiquity of a strong reduction of the infection rate during the initial days of the epidemic in all data sets that we studied (results of Belgium, Spain and France are available in Figure. S5). We tested this idea by computing the number of recovered cases that have lost their immunity against the virus after 50 days of the start of the epidemic. This number, which we call potential reinfec-
tions, is a proxy for the difficulty of capturing $\tau$. We consider a scenario similar to NYC, with equal population and equal initial and final infection rates $\beta$, but with different timing and effectiveness of lockdowns (Figure 4DE). The effectiveness is measured by the relative change between the infection rate pre- and post-lockdown. Simulation data supports our hypothesis since the number of potential reinfec-
tions is both close to zero and independent of $\tau$ when lockdowns are quickly established and/or when they are very effective with infection rate drops $> 90\%$.

Although we confirmed the potential of EAKF algorithms to distinguish the duration of immune memory during an ongo-
ing epidemic, we also noted that the application of our methods is bounded by the expected control measures that are aimed to reduce epidemic progression, i.e., to decrease the infection rate.

**Potential consequences of immunity on post-pandemic COVID-19 dynamics**

How could the immune memory for COVID-19 affect a secondary wave of infection? We tackle this by integrating the final state of the EAKF ensembles of NYC with our COVID-19 model deterministically. To account for the relaxation of social distancing measures we include a linear increase of the infec-
tion rate during the month of July, specifically, $\beta$ doubles by the 1st of August and remains constant from then on, which is a conservative scenario. In terms of the effective number of secondary infections $R_e^2$, a doubling of $\beta$ is equivalent to an $R_e$ increase from $0.7$ to $1.3$ (Extended data).

Figure 5 shows the model forecast of daily deceases due to COVID-19 considering the lower and upper bounds of the 95% CI, $\tau = 80$ and $\tau = 288$ days, respectively. First, in this sce-
nario where social distancing is only slightly relaxed and where the infection rate remains constant from then on, a new epi-
demic wave in terms of deceases would shortly take place. Its precise timing will depend strongly on the number of ICU beds available, but it can be expected to start in mid September. Moreover, without further social distancing measures during this second epidemic wave, we anticipate that it could last up until January and beyond.

This is due to the fact that, during the first wave, most of the population did not develop immunity to the virus and hence is yet susceptible through the second wave. Such a secondary peak has already been suggested in other specific scenarios$^{23,25}$.

However, if we focus on the maximum effect that different $\tau$s have in the short run, we find that, although the median trajec-
tory is independent of $\tau$, the confidence region is narrower for $\tau = 80$ days. In fact, we expect the immune memory to be relevant only after a considerable fraction of the population has undergone a first infection by COVID-19, or in the case that the time between epidemic waves (or intermittent social distancing) is shorter than that of $\tau$ where there is enough time to build a sufficiently large pool of immune population.

**Discussion**

We propose an alternative approach for estimating the duration of immunity. The protocol relies on the computational analy-
sis of epidemiological time series, which requires far fewer resources and may be deployed faster than its alternatives. Although longitudinal serological studies may be preferred, the evidence for immunity they provide is as indirect as the one we may detect in epidemiological data series. In fact, a direct experimental test of human immunity to SARS-CoV-2 would require intentionally infecting and monitoring recovered human patients with the virus, which would be highly controversial, although this approach has been tested in monkeys$^{26}$.

To circumvent this, serological studies obtain indirect evi-
dence based on the premise that antibody prevalence equates immunity, which is generally accurate. However, this is not the case for all diseases. Different mechanisms of persistence deployed by pathogens can uncouple antibody memory from

---

$^1$We refer to the basic reproductive number as the initial number of secondary infections, and to the effective reproduction number as the effective number of secondary infections.
actually being protected against the disease and/or being asymptomatic. Moreover, the effect of immunity on mortality series can hardly be mimicked by any other factors and draws information from field data. Thus, its standard of evidence for immunity is not necessarily lower than the one traditionally employed.

Despite all these points in its favor, the reach of the protocol in its current form is limited, and some requirements must be satisfied to discern immunity. Data series must have surpassed the peak following social distancing measures, which will increase the time necessary to begin a proper examination. In this regard, it is worth noting that capturing $\tau$ was highly dependent on lockdown policies, as evidenced by our potential reinfec
tions metric. The maximum portion of infected people in the population must be sufficiently large for there to be a signal. However, most regions will implement comparable measures to reduce the number of deceased and its growth that make the signal barely distinguishable. In some cases, different stages of social alarm stratified with political or legal restrictions of varying strength are what makes for very volatile infection rates or completely renders changes in immunity irrelevant to early population mortality.

However, segregating exposure and likeliness of infection should improve signal detection as all individuals are not equally likely to be infected. On the one hand, long-lasting cross-immunity with other coronaviruses can significantly reduce the susceptible population$^{27,28}$, and on the other hand, re-infections are most likely occurring in only a subset of the population (such as the working as opposed to the non-working population, age-based classifications, or metropolitan vs suburban or rural). A second way of improving immunity would be to use another observable on top of the deceased during data assimilation. In fact, predictions would improve considerably should data of the infected population be reliable and independent of the limited availability of PCR tests. In addition, the improper mapping of field-measured variables (the “confirmed”, sampling-biased metric) to model variables (exposed, asymptomatic, mild, severe and critical populations) prevents predictability.

But leaving aside reliability in the field tracking of epidemiological variables, it is also worth noting that the protocol is unworkable without a moderately predictive model. Concomitantly, having an accurate model requires some knowledge of the disease’s progression, symptomatology, and outcomes, as well as any notable resources or clinical agents involved in them (as in this case were ICU beds or oxygen). Still, none of these requirements is particularly unlikely to be reached during emergent pandemics. For instance, all of them had been satisfied after 3 months of COVID-19. And the information needed to produce a reasonable model was already public after the second month.

Lastly, perhaps the most significant obstacle in this and more conventional approaches is their inability to discriminate heterogeneity in immunity$^{29}$ from groups of recovered patients that have experienced varying degrees of symptomatology. Indeed, patients with many kinds of symptoms and/or peak viral loads may vary in their development of immunity. It could be, for instance, that mild cases do not result in enduring immunity, or result in a shorter immune span, than severe or critical cases. If that were the case, our approach would similarly identify a single overall value for immunity from the statistical overlap of different genuine immunity times, offering a weighed, non-real centrality measure of all immune times in the population.

All these things considered, the present protocol can be thought of as an additional first-hand tool that can always provide necessary evidence in the early stages of a pandemic, until more and varied methods can be deployed.

Now, several issues have arisen surrounding persistence and immunity in COVID-19 throughout the last months. For the majority of the time, the best estimate for immunity to SARS-CoV-2 the community could work with was a presumed range stemming from phylogenetic comparisons pertaining seasonal human coronaviruses like HCoV-OC43 and HCoV-HKU1$^{23}$. Nevertheless, the standard of evidence of phylogenetic assumptions is not very reliable, particularly with regards to microorganisms. According to these suppositions, COVID-19 may elicit immunity lasting from 6 months to 2 years.

Because these were potentially inaccurate measures, early cases of apparent reinfection sparked controversies, and even now as some countries are re-experiencing outbreaks recurring positives are a concern. Our work adds on to other very recent publications that appear to indicate immunity will last at least several months$^{10}$. In particular, a study has observed T cell immunity for SARS-CoV-2 not only in asymptomatic and mild patients, but also in unexposed individuals. This suggests both that the susceptible population has been overestimated and that there are signs of lasting immune memory$^{26}$. In fact, they find similarities with immunity to SARS-CoV-1, pointing that SARS-CoV-2 is likely to have a comparable immune response. Moreover, recent experimental results show that although antibody production depends strongly on disease severity, it lasts at least three months$^{51}$ in line with our results. In this context, we provide further evidence that the currently recovered patients will maintain, on average, at the very least 3.5 months of immunity, most likely around 5, and possibly no more than 7; so long as there are no significant differences due to case severity and cross immunity does not provide a far better protection to SARS-CoV-2 than exposition to SARS-CoV-2 itself.

Furthermore, we find that reinfections are a fundamental cornerstone of the current debate on immunity to SARS-CoV-2, especially concerning the development of a vaccine$^{32,33}$. Although the criteria to label reinfections as such have recently been settled$^{34}$, these are demanding. Indeed, to prove a reinfection the patient must have followed a positive-negative-positive PCR testing pattern with at least 28 days between the first and second positives to discard cases of viral remnants$^{38}$. Additionally, it is desirable to have samples of both positives be sequenced and compared to further improve accuracy of re-infection labeling$^{36}$. Also, as in other human coronaviruses, it is highly probable that reinfections produce asymptomatic or mild
symptoms\textsuperscript{32,38}, in which cases re-testing is hardly expected or not provided by health institutions. However, this might not always be the case, and re-infections can lead to worse symptoms\textsuperscript{39}. In general, the probability that a person is symptomatic during both infections, that has been tested negative in between and that samples of both positives are kept and sequenced is rare at best, which highlights the need for surveillance of SARS-CoV-2 reinfections (see also Addendum for further comments on our results).

While we recognize the complexity of the human immune response to SARS-CoV-2, as it is to many other viruses, we trust that our work contributes to a more solid comprehension of the epidemiological implications of this response.

Methods

Data acquisition

We obtained death counts of COVID-19 aggregated by country and USA county from the COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University\textsuperscript{19} (last updated on July 9th), and information of ICU beds from a variety of sources depending on the region of study (for the case of NYC see the city’s coronavirus tracker). We used Worldometer to obtain the populations of the regions and countries we selected for analysis\textsuperscript{41}. We also used data from the Oxford COVID-19 Government Response Tracker to find the days that different social distancing measures took place in some countries\textsuperscript{42}.

Epidemiological model

We introduced a compartmental model that exploits what is currently known about COVID-19 progression and associated accessible data such as the fraction and times at which different infected cases recover or worsen (Extended data: Table S1). Namely the compartments are: susceptible (\(S\)), exposed to the virus but not yet contagious (\(E\)), infected and contagious but asymptomatic (\(I_a\)), with mild symptoms (\(I_m\)), with severe symptoms (needs hospitalization - \(I_h\)), and critical symptoms (requires urgent admittance to an ICU - \(I_c\)); recovered cases (\(R\)) and the deceased (\(D\)).

The basic reproductive number, \(R_0\) and its temporal-dependent counterpart \(R_e\) (effective reproductive number) are composite parameters that integrate information on not only the infection rate but also the contact rate, susceptible population, and most importantly model architecture\textsuperscript{43,44}. For this reason, we have prioritized the use of the infection rate \(\beta\) throughout. However, we have used \(R_e\) sparingly due to its biological relevance, which lies in whether it is larger/smaller than the unit, indicating whether the outbreak is expected to continue. To compute \(R_e\) we have applied the Next Generation Matrices (NGM) algorithm to our model\textsuperscript{19}, hence \(R_e\) is the largest eigenvalue of the NGM \(K_e=T S\) where \(T\) and \(S\) are respectively the transmissions and transitions matrices (see Extended data for more details). A sensitivity analysis of \(R_e\) with respect to the model parameters is available in Figure S6.

Data assimilation

The EAKF filtering method consists in propagating and updating ensemble members, which constitute a probabilistic description of the state variables and model parameters\textsuperscript{33}. Ensembles are samples of the distributions that the variables are expected to have. In our case, the time-dependent state variables are the infection rate \(\beta\), the immunity memory \(\tau\) and the population in each compartment of the model. We also introduced a dummy variable \(\delta\) that does not affect the model results against which to test the ensemble dynamics of \(\tau\). The time-dependent observable is the number of daily deceases officially reported, to which we applied a 2 week running average to account for miscommunications and reporting delays.

In the data assimilation step, the ensemble members are integrated with the model to obtain their expected state at the time of the succeeding observation. Next, together with the likelihood distribution of the actual observation, the algorithm calculates the posterior probability assuming that all distributions are normal. Lastly, the unobserved state variables are updated according to their correlation with the observable. For the assimilation of the next data-point, the posterior probability then becomes the prior. A more detailed description of the protocol is available in the Extended data.

Importantly, considering that \(\tau\) did not correlate linearly with the observable, we used rank correlations instead to update both \(\tau\) and \(\delta\). We also used a 3% inflation in the ensemble variance of all variables except \(\tau\) and \(\delta\) since they showed no convergence problems. We have run 100 EAKF instances with ensemble sizes of 200 members. The days in which confinement measures took place (school closing, lockdown...) we added a 200% inflation to better accommodate parameter discontinuities.

Addendum

December 17, 2020

After the publication of this manuscript in the medRxiv repository by the end of July 2020 (https://doi.org/10.1101/2020.07.22.20160028), we decided to submit it to several scientific journals for peer review. Some reviewers raised a few issues that unfortunately led to a rejecting editorial consideration even though, in our opinion, they could be argued in their entirety. We take this opportunity to provide a precise answer to these issues further explaining the contributions of this work and also its limitations.

Rationale and context of this work

By January 2020 both the scientific community and the broader public were already aware of the novel coronavirus SARS-CoV-2, by February it spread without difficulty, and on March 11th the World Health Organization declared the COVID-19 pandemic. During March, most of the countries closed schools, public transport and established a variety of social
distancing measures. Initial debates focused on sources of infection (contact surfaces, aerosols), its infectivity (the now well-known $R_0$), the importance of social distancing, geographical dynamics and, the development of immunity after recovery\cite{1,2}.

While some of these debates have been already clarified, questions around SARS-CoV-2 immunity remain nowadays greatly unresolved\cite{1}. In this work, we provided an early estimate of the duration of immunity developed by recovered people after SARS-CoV-2 infections, it being between 3 and 7 months with a 90% CI from New York City (NYC) data. The main concerns raised by readers were

1. the major conclusion is flawed as we obtain a short duration of immunity,
2. this question can only be resolved with approaches characteristic of Molecular Biology,
3. many, many factors determine immunity as to be defined with a single parameter,

which, although already examined in the introduction and the discussion, we will now further review.

**Immunity can be short lasting, and reinfections may be largely underestimated**

The principal aim of this work was to explore alternative approaches to assess the duration of immunity given that longitudinal serological studies are time- and resource-consuming. Its main result, which is the duration of immunity, has been questioned for two reasons: immunity appears to last only a few months, and should that be the case, the number of reinfections reported is far less than expected.

Firstly, our estimate of an immune memory lasting several months is in line with initially published results\cite{3}. Moreover, as in the manuscript’s discussion, while we provide a defined range of immunity duration it has to be considered with caution. Partly because not a single range nor a single value can fully describe the high complexity of immunity derived from the ample heterogeneity in viral charges, secondary exposures, disease severity and, individual immune responses\cite{4}. Note that reports on reinfections within a few months after the first infection also support our lower bound to the duration of immunity\cite{5}.

Secondly, while some propose that reinfections are a rare event, others argue that most of them are going unnoticed. However, we believe both stances are appropriate as suggests the COVID-19 reinfection tracker\cite{6}. Confirmed reinfections are indeed rare, but the figure grows two orders of magnitude if we also consider suspected reinfections: from 30 vs. 1700, respectively. This disparity is partly explained by the lack of genetic proof in suspected cases of reinfections. In addition, most reinfections are hardly detectable as they might present even milder symptoms compared to the first infection.

**Contributions from an alternative approach to the molecular assessment of immunity**

The fundamental methodological handicap of our approach is the difficulty with which the duration of immunity is captured during an intense epidemic in which most regions will implement social distancing and confinements as principal contention measures.

In fact, our protocol can only robustly obtain the duration of immunity if reinfections are a significant driver of the epidemic dynamics, as evidenced by the success in treating synthetic data and by our reinfections metric for the case of NYC. Although this poses a major obstacle to an accurate estimation of the duration of immunity for experimental data of the COVID-19, we found that NYC data deviated significantly from a reinfection-free scenario, which led to a significant estimation of this parameter.

The estimate we provide relies on a simple compartmentalized model, a common approach in the study of epidemics with its limitations, yet tailored to the typical stages of SARS-CoV-2 infection in which the effects of reinfections produced by immunity loss cannot be mimicked by any other factor. To this model, we applied state-of-the-art probabilistic methods that have already been applied previously with success to highly non-linear systems like weather forecasting, and other epidemics\cite{6,7}. For this reasons, we believe that although limited by data, we provided a sound initial estimate on immunity duration of comparable value to other approaches after only four months since the declaration of the pandemic.

**Conclusion**

In this work, we demonstrate that epidemiological models together with state-of-the-art numerical methods are complementary to traditional approaches in providing estimates of the duration of immunity during the COVID-19 pandemic. Finally, the success in analysing synthetic data highlights the potential of this methodology for epidemiological studies beyond COVID-19. We hope that this and other lessons will contribute to a better response to future pandemics.

**Data availability**

**Underlying data**

Daily time series summary tables, including confirmed, deaths and recovered are available from: https://github.com/CSSEGISandData/COVID-19/tree/master/csse_covid_19_data/csse_covid_19_time_series

Archived time series data as at time of publication: http://doi.org/10.5281/zenodo.4452124\cite{7}

**Extended data**

This project contains the following extended data:

- COVID-19 epidemiological model
- Introduction to Ensemble Adjustment Kalman Filter algorithms
- Figure S1. A minimal SEIRS model is not completely equivalent to our COVID-19 model.
- Figure S2. Model sensitivity analysis.
- Figure S3. Impact of COVID-19 upon different countries and regions.
- Figure S4. Daily deceases of COVID-19 upon different countries and regions.
- Figure S5. EAKF results for Belgium, Spain and France.
- Figure S6. Parameter sensitivity of R0.
- Table S1. List of parameters and their values references used throughout.

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).
PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

40. COVID-19 Data Repository by the Center for Systems Science and Engineering at Johns Hopkins University. Reference Source

41. Worldometer. Reference Source


PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text


PubMed Abstract | Publisher Full Text | Free Full Text


Open Peer Review

Current Peer Review Status: ×

Version 1

Reviewer Report 26 April 2021

https://doi.org/10.5256/f1000research.31524.r80253

© 2021 Oliveira J. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Juliane F. Oliveira
Center of Data and Knowledge Integration for Health (CIDACS), Salvador, Brazil

Using mathematical modelling, the work submitted by Poyatos and colleagues tries to estimate from series of death and hospitalisations need the interval of acquired immunity by an infected individual by SARS-CoV-2.

As pointed out by the authors, longitudinal serological studies are required to determine the duration of immunity to a virus. Such studies consider individual response levels for the disease, which for many diseases it is also influenced by age. These characteristics can not be studied from ecological data of counts of mortalities, or cases, or hospitalisation needs.

Additionally, the authors carry out significant misinterpretations on the model construction, which invalidate the analysis performed. For instance, they fail to interpret the disease's dynamics and draw the pathway of the individuals from susceptibility to an outcome as recovered or death. There is a transition between exposed and mild infections where asymptomatic infections compulsory will be a mild infection. Other confusions are seen between the basic reproduction number, a value estimated at the beginning of the disease dissemination, and the effective reproduction numbers.

The methods and data analysed cannot estimate such a complex measure: the immunity period for a disease.

Is the work clearly and accurately presented and does it cite the current literature?
Partly

Is the study design appropriate and is the work technically sound?
No

Are sufficient details of methods and analysis provided to allow replication by others?
Partly
If applicable, is the statistical analysis and its interpretation appropriate?
No

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
No

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Mathematics, Dynamical systems, Singularity Theory, Mathematical Modeling of Infectious Diseases

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

---

**Author Response 30 Apr 2021**

**Juan Poyatos**, Spanish National Center of Biotechnology, Madrid, Spain

**Comment.** As pointed out by the authors, longitudinal serological studies are required to determine the duration of immunity to a virus. Such studies consider individual response levels for the disease, which for many diseases it is also influenced by age. These characteristics can not be studied from ecological data of counts of mortalities, or cases, or hospitalisation needs.

**Response.** The reviewer’s main concern is that immunity time can only be ascertained through longitudinal serological studies. The reviewer appears to overlook in this argument the analyses that we performed on synthetic data before studying actual coronavirus mortality. These analyses demonstrate the opening premise that immunity time can be discerned significantly despite intrinsic limitations and an obscure infection rate. Thus, the results of this part of the manuscript (section 2) constitute statistical proof of how our approach quantifies immunity time.

Furthermore, we at no point say in our manuscript that serological studies are the only way to estimate immunity time. Indeed, note that a posterior study concocted and added to the repositories after this manuscript of ours was, replicated part of our approach and obtained some information on immunity. This study was recently published in Science [Saad-Roy et al., Science 370, 6518, 811-8, 2020] and thus represents a bibliographical endorsement of our approach.

**Comment.** Additionally, the authors carry out significant misinterpretations on the model construction, which invalidate the analysis performed. For instance, they fail to interpret the disease’s dynamics and draw the pathway of the individuals from susceptibility to an outcome as recovered or death. There is a transition between exposed and mild infections...
where asymptomatic infections compulsory will be a mild infection.

**Response.** The reviewer takes exception to a feature that seems to be the absence of an explicit transition between two compartments of the model, the “asymptomatic” and recovered patients. The criticisms seem to refer to said diverging feature between our rendition of covid19 etiology and her co-authored modeling work [Oliveira et al., Nat Comm 12, 333, 19798-3, 2021].

The feature in question, the transition between asymptomatic and recovered patients, is present in their model but not explicit in ours. Oliveira et al. consider that some people are exposed to the virus, infected, and promptly become immune without showing any symptoms at all (something that has been profusely taken for granted since the beginning of the pandemic, but rarely well demonstrated), and writes this as a specific term in their equations. In contrast, we consider that all infected patients will develop either headache, digestive problems, fever, or a slight cough during 0 to 15 days. Both things are not incompatible and, as a matter of fact, the nature of our bibliographical parameters as measures of centrality is not incompatible with a subset of these asymptomatic patients indeed becoming immune. Therefore, our model does not fail the reality being modelled any more than one whereby this transition is explicitly represented.

But, even if it was the case that our model was compartmentalized differently, this would not necessarily change anything. When using models for prediction, not every change to the model is relevant for predictivity. Indeed, a conventional SEIRS model, which we evaluated in our study before the analyses with the advanced one that the reviewer takes exception to, is well beyond capable of predicting coronavirus mortality when combined with ensemble filtering approaches. And it does so with a structure more general and uninformed than either our model or other aesthetically different iterations used, such as the reviewer's very own.

**Comment.** Other confusions are seen between the basic reproduction number, a value estimated at the beginning of the disease dissemination, and the effective reproduction numbers.

**Response.** We kindly, but again strongly, disagree with the reviewer in the existence of any kind of confusion regarding the basic reproduction number (R0) and the effective reproduction number (Re) along our manuscript.

The first time we mention R0 we call it "initial number of secondary infections" (Results section 1, paragraph 3) and is totally equivalent to the basic reproduction number as defined by the reviewer and as evidenced by the standardized nomenclature R0.

Later, we mention "the effective number of secondary infections Re" (Results section 4, paragraph 1), which is totally equivalent to the "effective reproduction number" that the reviewer mentions. In this case, we are describing the reproduction number after the start of the disease in agreement with the reviewer's description and, again, as evidenced by the use of the standard nomenclature Re.
Moreover, in the methods section we refer to R0 as the "basic reproductive number" and Re as the "effective reproductive number" in literal agreement with the reviewer description of these parameters. Furthermore, that we call Re the "temporal-dependent counterpart" of R0 highlights what the reviewer points out: that R0 is fixed while Re is time-dependent.

Finally, our computation of R0 and Re follow the standard procedure using the Next Generation Matrices, which unsurprisingly is the same method the reviewer used in a co-authored work [Oliveria et al, Nat Comm 12, 333,19798-3,2021]. Hence, we regret that using "number of secondary infections" instead of "reproductive number" even when preserving the standard notation R0 and Re might have caused such confusion in the reviewer. We have added a brief note in a new version of our manuscript to make this clear when mentioning both R0 and Re (link to reference [23] in Results section 1, paragraph 3 and Results section 4 paragraph 1).

We thank the reviewer for her time. We hope that our clarifications in this response will be positively valued and that she now considers our manuscript approved for publication.

**Competing Interests:** The authors declare no competing interests.